Literature DB >> 8345441

Local reactions to depot leuprolide therapy for central precocious puberty.

P K Manasco, O H Pescovitz, R M Blizzard.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8345441     DOI： 10.1016/s0022-3476(05)81720-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  8 in total

1.  Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty.

Authors:  Ji Woo Lee; Hyung Jin Kim; Yun Mee Choe; Hee Suk Kang; Soon Ki Kim; Yong Hoon Jun; Ji Eun Lee
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-09-30

2.  Imaging of recurrent intramuscular granulomatous masses induced by depot injection of leuprorelin.

Authors:  Emily N Vinson; Andresa Braga-Baiak; Leslie G Dodd; Salutario Martinez
Journal:  Skeletal Radiol       Date:  2011-08-23       Impact factor: 2.199

3.  Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot.

Authors:  V N de Brito; A C Latronico; I J Arnhold; L S Lo; S Domenice; M C Albano; M C Fragoso; B B Mendonca
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

4.  Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.

Authors:  Lawrence A Silverman; E Kirk Neely; Gad B Kletter; Katherine Lewis; Surya Chitra; Oksana Terleckyj; Erica A Eugster
Journal:  J Clin Endocrinol Metab       Date:  2015-03-24       Impact factor: 5.958

Review 5.  Central precocious puberty: current treatment options.

Authors:  Franco Antoniazzi; Giorgio Zamboni
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 6.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

7.  Bilateral injection-site granuloma by subcutaneous administration of luteinizing hormone-releasing hormone analogue: a case report.

Authors:  Riko Kitazawa; Fukashi Yamamichi; Toshiharu Hidaka; Shinichi Morishita; Takeshi Kondo; Kiyoshi Mori; Sohei Kitazawa
Journal:  Cases J       Date:  2009-09-15

8.  An open label, multicenter clinical trial that investigated the efficacy and safety of leuprorelin treatment of central precocious puberty in Chinese children.

Authors:  Xiaoping Luo; Ling Hou; Yan Zhong; Cheng You; Yu Yang; Xian Wu; Pin Li; Shasha Zhou; Wenjuan Qiu; Huiwen Zhang; Ying Liu; Ye Qian; Feihong Luo; Ruoqian Cheng; Yuhua Hu; Haihong Gong; Qing Wang; Zhuangjian Xu; Hongwei Du; Feiyu Lu; Junfen Fu; Xuefeng Chen; Winston Wang; Ziheng Guo
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.